CN110062761B - 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途 - Google Patents

取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途 Download PDF

Info

Publication number
CN110062761B
CN110062761B CN201780075930.5A CN201780075930A CN110062761B CN 110062761 B CN110062761 B CN 110062761B CN 201780075930 A CN201780075930 A CN 201780075930A CN 110062761 B CN110062761 B CN 110062761B
Authority
CN
China
Prior art keywords
imidazo
pyridin
methyl
oxo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780075930.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110062761A (zh
Inventor
C.C.克罗维安
M.A.勒塔维克
J.C.瑞施
D.A.鲁多弗
A.S.约翰逊
B.M.斯坦内
J.L.沃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN202210460371.2A priority Critical patent/CN114989164B/zh
Publication of CN110062761A publication Critical patent/CN110062761A/zh
Application granted granted Critical
Publication of CN110062761B publication Critical patent/CN110062761B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201780075930.5A 2016-10-06 2017-10-05 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途 Active CN110062761B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210460371.2A CN114989164B (zh) 2016-10-06 2017-10-05 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404798P 2016-10-06 2016-10-06
US62/404798 2016-10-06
PCT/US2017/055278 WO2018067786A1 (en) 2016-10-06 2017-10-05 Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210460371.2A Division CN114989164B (zh) 2016-10-06 2017-10-05 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途

Publications (2)

Publication Number Publication Date
CN110062761A CN110062761A (zh) 2019-07-26
CN110062761B true CN110062761B (zh) 2022-05-13

Family

ID=61831306

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780075930.5A Active CN110062761B (zh) 2016-10-06 2017-10-05 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途
CN202210460371.2A Active CN114989164B (zh) 2016-10-06 2017-10-05 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210460371.2A Active CN114989164B (zh) 2016-10-06 2017-10-05 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途

Country Status (18)

Country Link
US (4) US10617676B2 (https=)
EP (1) EP3523311B1 (https=)
JP (1) JP7001682B2 (https=)
KR (1) KR20190056435A (https=)
CN (2) CN110062761B (https=)
AR (1) AR109810A1 (https=)
AU (1) AU2017340602A1 (https=)
BR (1) BR112019006691A2 (https=)
CA (1) CA3038820A1 (https=)
CL (1) CL2019000882A1 (https=)
EA (1) EA201990848A1 (https=)
ES (1) ES2950881T3 (https=)
IL (1) IL265757A (https=)
MA (1) MA46470A (https=)
MX (1) MX2019003980A (https=)
PH (1) PH12019500676A1 (https=)
TW (1) TW201819376A (https=)
WO (1) WO2018067786A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
ES2791252T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
US11492345B2 (en) * 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
WO2019232209A1 (en) 2018-05-30 2019-12-05 Praxis Precision Medicines, Inc. Ion channel modulators
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
CN109499614B (zh) * 2018-12-12 2021-06-04 怀化学院 MOPs负载双齿螯合型金属催化剂及其制备方法
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
SG11202112405VA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
JP7667097B2 (ja) * 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
KR20220024403A (ko) * 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
CN113993868A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途
CN113950357A (zh) 2019-06-14 2022-01-18 詹森药业有限公司 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
US12552797B2 (en) 2019-11-27 2026-02-17 Praxis Precision Medicines, Inc. Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine
AU2021233745B2 (en) * 2020-03-11 2024-05-02 Anygen Co., Ltd. Composition for anti-diabetes and anti-obesity comprising novel compound
BR112022023559A2 (pt) * 2020-05-21 2023-01-24 Stemsynergy Therapeutics Inc Inibidores de notch e seus usos
CN112939986B (zh) * 2021-02-18 2023-06-13 新乡医学院 一种吡唑并嘧啶类化合物的合成方法
KR20230037391A (ko) * 2021-09-09 2023-03-16 애니젠 주식회사 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물
MX2024013240A (es) 2022-04-26 2024-12-06 Praxis Prec Medicines Inc Tratamiento de trastornos neurologicos
WO2025224308A1 (en) * 2024-04-25 2025-10-30 Scenic Immunology B.V. Qpctl inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101968A1 (en) * 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compound and medicinal composition containing the same
CN102264743A (zh) * 2008-11-25 2011-11-30 罗彻斯特大学 Mlk抑制剂及其使用方法
JP2012188363A (ja) * 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
CA2262502C (en) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
AU2001270149A1 (en) * 2000-06-26 2002-01-08 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
EP1490364B1 (en) 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1720860A1 (en) 2004-02-18 2006-11-15 AstraZeneca AB Triazole compounds and their use as metabotropic glutamate receptor antagonists
US7820654B2 (en) 2004-09-23 2010-10-26 Dr. Reddy's Laboratories Ltd. Pyrimidine compounds, process for their preparation and compositions containing them
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
TWI443090B (zh) 2007-05-25 2014-07-01 Abbvie Deutschland 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CN101842357A (zh) 2007-08-30 2010-09-22 武田药品工业株式会社 取代的吡唑衍生物
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
WO2009118187A1 (en) 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
JPWO2009157196A1 (ja) 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
NZ590688A (en) 2008-08-05 2012-09-28 Daiichi Sankyo Co Ltd imidazo[4,5-b]pyridin-2-one derivatives
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
EP2579717A4 (en) * 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶ｃｄｋ９激酶抑制劑
SG11201506687RA (en) 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
CA2918242C (en) 2013-07-31 2022-06-21 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2016015097A1 (en) 2014-07-28 2016-02-04 Safemate Australia Pty Ltd Systems and methods for making personal emergency information available to third parties
ES2791252T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
HRP20200410T1 (hr) * 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
SG11202112405VA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
CN113950357A (zh) 2019-06-14 2022-01-18 詹森药业有限公司 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
CN113993868A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101968A1 (en) * 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compound and medicinal composition containing the same
CN102264743A (zh) * 2008-11-25 2011-11-30 罗彻斯特大学 Mlk抑制剂及其使用方法
JP2012188363A (ja) * 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CaMKⅡ介导的谷氨酸受体磷酸化;毛利民等;《Acta Physiologica Sinica》;20141231;第66卷(第3期);第365-372页 *
Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis;Mark E. Layton et al.;《Bioorganic & Medicinal Chemistry Letters》;20160111;第26卷(第2016期);第1260-1264页 *

Also Published As

Publication number Publication date
EP3523311B1 (en) 2023-06-07
MX2019003980A (es) 2019-06-10
WO2018067786A1 (en) 2018-04-12
US20230000833A1 (en) 2023-01-05
JP2019530695A (ja) 2019-10-24
CN114989164A (zh) 2022-09-02
PH12019500676A1 (en) 2019-12-02
EP3523311A4 (en) 2020-03-18
US10617676B2 (en) 2020-04-14
TW201819376A (zh) 2018-06-01
US20210069155A1 (en) 2021-03-11
JP7001682B2 (ja) 2022-01-19
EP3523311C0 (en) 2023-06-07
CN110062761A (zh) 2019-07-26
CL2019000882A1 (es) 2019-06-21
IL265757A (en) 2019-06-30
AR109810A1 (es) 2019-01-23
CN114989164B (zh) 2024-08-13
EP3523311A1 (en) 2019-08-14
AU2017340602A1 (en) 2019-04-18
US20230338341A1 (en) 2023-10-26
US20180125826A1 (en) 2018-05-10
US11207298B2 (en) 2021-12-28
MA46470A (fr) 2019-08-14
US11759455B2 (en) 2023-09-19
EA201990848A1 (ru) 2019-08-30
ES2950881T3 (es) 2023-10-16
CA3038820A1 (en) 2018-04-12
BR112019006691A2 (pt) 2019-06-25
KR20190056435A (ko) 2019-05-24

Similar Documents

Publication Publication Date Title
CN110062761B (zh) 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其用途
JP7369743B2 (ja) 置換４－アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
CN105209468B (zh) 取代的7‑氮杂二环化合物以及它们作为食欲素受体调节剂的用途
US11530210B2 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
AU2016255431B2 (en) Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
CN111032656A (zh) 杂环化合物激酶抑制剂及其药物组合物和应用
KR20210013145A (ko) 키나아제 억제제로서 헤테로시클릭 화합물, 헤테로시클릭 화합물을 포함하는 조성물 및 그 사용 방법
CN104981472A (zh) 杂芳族化合物及其作为多巴胺d1配体的用途
KR20160012194A (ko) 이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도
CA3143102A1 (en) Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
CN113993868A (zh) 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途
EP4590396A1 (en) Pcsk9 inhibitors and methods of use thereof
US20220274984A1 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
HK40028694A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
HK40028694B (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant